Oruka Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oruka Therapeutics, Inc. (Nasdaq: ORKA) on December 11, 2025. The report discloses changes to the Company's Board of Directors, specifically the resignation of one director and the appointment of another.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Stock Option Grant: 35,000 shares of common stock granted to the new director, vesting over 36 months.
- Annual Cash Retainer (Board Member): $40,000.
- Annual Cash Retainer (Compensation Committee Chair): $12,000.
- Annual Cash Retainer (Audit Committee Member): $7,500.
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Resignation: Cameron Turtle resigned as a member of the Board on December 11, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices, nor was it a removal for cause.
- Appointment: Christopher Martin was appointed as a Class II director, with a term expiring at the 2026 annual meeting of stockholders.
- Committee Assignments: Mr. Martin was appointed Chair of the Compensation Committee and a member of the Audit Committee.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the Company's business strategy or clinical pipeline. The report focuses solely on the governance changes. The Board determined that Mr. Martin qualifies as an independent director and a non-employee director under applicable SEC and Nasdaq rules. No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified involving Mr. Martin.
Key Facts for Investor Verification
- Verify the independence status and potential conflicts of interest for the newly appointed director, Christopher Martin, given his recent role at Verona Pharma (acquired by Merck) and current board seat at Edgewise Therapeutics.
- Confirm the total number of directors on the Board following the resignation of Cameron Turtle and the appointment of Christopher Martin.
- Review the full text of the Offer Letter (Exhibit 10.1) for any additional compensation terms or conditions not summarized in the 8-K.
- Monitor future filings for any financial updates, as this 8-K contains no operational or financial performance data.